Processa Pharmaceuticals Management
Management criteria checks 3/4
Processa Pharmaceuticals' CEO is George Ng, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is $714.03K, comprised of 22.3% salary and 77.7% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $17.42K. The average tenure of the management team and the board of directors is 4.3 years and 4.8 years respectively.
Key information
George Ng
Chief executive officer
US$714.0k
Total compensation
| CEO salary percentage | 22.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Dec 12
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Oct 20Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
Aug 12We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Jul 07We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate
Jan 20Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
Aug 26Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow
Jun 15What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?
Mar 15Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look
Jan 29How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?
Jan 20
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$12m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$714k | US$159k | -US$11m |
Compensation vs Market: George's total compensation ($USD714.03K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Insufficient data to compare George's compensation with company performance.
CEO
George Ng (50 yo)
1.3yrs
Tenure
US$714,031
Compensation
Mr. George K. Ng, Esq. JD serves as CEO of Processa Pharmaceuticals, Inc. since August 08, 2023 and serves as its Director since August 08, 2023 and served as its Director since August 08 2023 until 2024....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$714.03k | 0.61% $ 17.4k | |
| Co-Founder | 7.9yrs | US$186.64k | 2.81% $ 79.9k | |
| Co-Founder and Chief Development & Regulatory Officer | no data | US$321.73k | 0.67% $ 19.1k | |
| Co-Founder | 7.9yrs | US$1.04m | 0.89% $ 25.3k | |
| Co-Founder | 7.2yrs | US$1.02m | 0.36% $ 10.3k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Research | less than a year | no data | no data |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Management: PCSA's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$714.03k | 0.61% $ 17.4k | |
| Co-Founder | 7.2yrs | US$186.64k | 2.81% $ 79.9k | |
| Independent Director | 2.3yrs | US$83.00k | 0.022% $ 628.0 | |
| Member of Medical & Scientific Advisory Board | 4.8yrs | no data | no data | |
| Independent Chairman of Board | 7.3yrs | US$54.00k | 0.11% $ 3.3k | |
| Member of Medical & Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Medical & Scientific Advisory Board | 2.2yrs | no data | no data | |
| Independent Director | 2.4yrs | US$83.00k | 0.043% $ 1.2k | |
| Independent Director | 4.8yrs | US$54.00k | 0.088% $ 2.5k |
4.8yrs
Average Tenure
61.5yo
Average Age
Experienced Board: PCSA's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 15:51 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Processa Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| François Brisebois | Oppenheimer & Co. Inc. |